The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours.

ABSTRACT:

Aims

We investigated whether major gastrectomy influences the plasma exposure of regorafenib and treatment outcome.

Methods

Efficacy and pharmacokinetic data from 133 gastrointestinal stromal tumour patients included in a phase III trial were analysed. Patients were subdivided into 2 groups according to the extent of the gastrectomy (no/nonsignificant gastrectomy and major gastrectomy). Progression-free survival (PFS) on regorafenib was measured and regorafenib and its pharmacological active metabolites plasma exposure were measured.

Results

A total of 133 patient were included, of whom 27 underwent major gastrectomy. In patients with no/nonsignificant gastrectomy the median PFS was 145 (interquartile range 43-281) days. The PFS in patients with a major gastrectomy wa

SUBMITTER: Lubberman FJE 

PROVIDER: S-EPMC6783594 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature